|
|
|
|
|
Click Here to return To Results
|
|
|
|
During pregnancy, MG relapsed in 4 of 23 (17%) asymptomatic patients who were not on therapy before conception; in patients taking therapy, MG symptoms improved in 12 of 31 pregnancies (39%), remained unchanged in 13 (42%), and deteriorated in 6 (19%). MG symptoms worsened after delivery in 15 of 54 (28%) pregnancies. Anti-acetylcholine receptor antibody (anti-AChR ab) was positive in 40 of 47 mothers and was assayed in 30 of 55 newborns; 13 were positive and 5 of 55 (9%) showed signs of neonatal MG (NMG). All affected babies were seropositive. Pregnancy does not worsen the long-term outcome of MG. The course of the disease is highly variable and unpredictable during gestation and can change in subsequent pregnancies. The occurrence of NMG does not correlate with either maternal disease severity or anti-AChR antibody titer. Immunosuppressive therapy, plasmapheresis, and IV human immunoglobulins can be administered safely if needed. |
|
(click to filter results - removes previous filter)
gammaglobulin therapy,intravenous
immunosuppressive agents
myasthenia gravis
myasthenia gravis,neonatal
myasthenia gravis,prognosis of
myasthenia gravis,treatment of
plasmapheresis
pregnancy,neurologic complications in
prognosis
treatment of neurologic disorder
|
Click Here to return To Results
|
|